Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Regulatory & Safety

News in brief

Enzon approves pharma biz sale


Enzon stockholders have approved the sale of its pharmaceutical business, which has four marketed products and a manufacturing facility, to sigma-tau for an initial $300m (€214m).

By acquiring Enzon sigma-tau will gain a manufacturing facility in Indianapolis, Indiana, US and the marketed products Oncaspar, Adagen, DepoCyt and Abelcet.


The approval of Enzon’s stockholders comes after the company entered into a definitive agreement to sell the business to sigma-tau. Enzon will receive $300m from sigma-tau, plus an additional amount of up to $27m in milestone payments.


Furthermore, Enzon will receive royalties of five to 10 per cent on incremental net sales above a 2009 baseline.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Key Industry Events


Access all events listing

Our events, Events from partners...